Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392234 | 1.00 | MTNR1A (0.50) | MTNR1AMTNR1BMAPTHSD11B1MCL1 | |
| SCHEMBL6515251 | 0.85 | CNR1 (0.61) | MTNR1AMTNR1BCNR1CNR2SMN1; SMN2 | |
| SCHEMBL3390946 | 0.85 | CNR1 (0.61) | MTNR1AMTNR1BCNR1CNR2SMN1; SMN2 | |
| SCHEMBL6520141 | 0.79 | CNR1 (0.75) | MAPTCNR1CNR2KDM4EHTT | |
| SCHEMBL3395117 | 0.79 | CNR1 (0.75) | MAPTCNR1CNR2KDM4EHTT | |
| SCHEMBL3395386 | 0.75 | CNR1 (0.64) | MTNR1AMTNR1BMAPTCNR1CNR2 | |
| SCHEMBL3391235 | 0.75 | MTNR1A (0.51) | MTNR1AMTNR1BMCL1ADORA2AGAA | |
| SCHEMBL3393766 | 0.75 | MTNR1A (0.51) | MTNR1AMTNR1BMCL1ADORA2AGAA | |
| SCHEMBL6511965 | 0.75 | CNR1 (0.64) | MTNR1AMTNR1BMAPTCNR1CNR2 | |
| SCHEMBL6515896 | 0.72 | MTNR1A (0.43) | MTNR1AMTNR1BMAPTMCL1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370530-B1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | MTNR1A 604/4885MTNR1B 448/4885MAPT 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.